Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study.

Item

http://www.wikidata.org/entity/Q46244551

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Busulfex (i.v. BU) and CY regi ...... armacokinetics combined study.

@en

Busulfex

@nl

type

Item

label

Busulfex (i.v. BU) and CY regi ...... armacokinetics combined study.

@en

Busulfex

@nl

prefLabel

Busulfex (i.v. BU) and CY regi ...... armacokinetics combined study.

@en

Busulfex

@nl

P1476

Busulfex (i.v. BU) and CY regi ...... armacokinetics combined study.

@en

P2093

A M Saito

http://www.w3.org/2001/XMLSchema#string

H Sakamaki

http://www.w3.org/2001/XMLSchema#string

M Harada

http://www.w3.org/2001/XMLSchema#string

M Kami

http://www.w3.org/2001/XMLSchema#string

N Usui

http://www.w3.org/2001/XMLSchema#string

R Tanosaki

http://www.w3.org/2001/XMLSchema#string

R Ueda

http://www.w3.org/2001/XMLSchema#string

S Miyakoshi

http://www.w3.org/2001/XMLSchema#string

S Okamoto

http://www.w3.org/2001/XMLSchema#string

S Taniguchi

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular basis of ethnic differences in drug disposition and response.

An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease.

Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation.

Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.

Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-

Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission.

Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity.

P2888

bmt.2008.372

P304

611-617

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2008.372

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23475982

http://www.w3.org/2001/XMLSchema#string

P698

19011665

http://www.w3.org/2001/XMLSchema#string